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CASE PRESENTATION
A 36-year-old African American man was evaluated in
the emergency room at Wishard Memorial Hospital fol-
lowing a motor vehicle accident. The patient’s car was hit
from behind, and as he fled the scene of the accident, he
fell and rolled down a hill. He was subsequently detained
by police and brought to the hospital for evaluation of
diffuse trauma and myalgias. In the emergency room, he
was awake and alert but tachycardic, with a heart rate of
136 beats/min, a respiratory rate of 20 breaths/min, and
a blood pressure of 104/57 mm Hg. The trauma team’s
evaluation disclosed no significant injuries. However, he
was admitted for evaluation and hydration, and because
of an elevated serum creatinine level.
His medical history was remarkable for a solitary right
kidney, excessive alcohol intake, and use of crack cocaine,
but he denied illicit intravenous drug use. He was taking
no prescribed medications and had no history of diabetes,
hypertension, or past surgeries. He had no known aller-
gies. The baseline serum creatinine had been 1.2 mg/dL
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8 years prior to admission. A review of systems was neg-
ative, with the exception of diarrhea over the previous
48 hours.
Physical examination revealed a somewhat anxious,
mildly obese black man in no apparent distress. The ex-
amination was otherwise within normal limits except for
diffuse mild muscle pain.
Laboratory values on admission revealed: serum
sodium, 139 mEq/L; potassium, 4.9 mEq/L; chloride, 103
mEq/L; bicarbonate, 9 mEg/L; creatinine, 2.0 mg/dL;
total protein, 6.5 g/dL; albumin, 3.5 g/dL; calcium,
9.2 mg/dL; bilirubin, 1.7 mg/dL; hemoglobin, 14.1 g/dL;
white blood cell count, 12,600/mm2 with a normal dif-
ferential; platelets, 245,000; a normal peripheral smear;
and lactate, 4.7 mEq/L. Urinalysis disclosed cloudy urine
containing >300 mg/dL protein; pH, 5.5; 4+ hemoglobin
on dipstick; 5 red blood cells/high-power field; and no
casts, but the urine was qualitatively positive for myo-
globin. The initial serum creatine phosphokinase (CPK)
was 14,565 units/mL; aspartate aminotransferase (AST),
2470; and alanine aminotransferase (ALT), 1785 U/mL.
The patient was aggressively hydrated with normal
saline at 200 mL/hour. After receiving 1 L, the infusion
was altered to 5% glucose with 3 ampules of bicarbonate
added per liter and administered at 300 mL/hour. Twenty-
four hours following admission, the patient’s laboratory
values were: sodium, 133 mEq/L; potassium, 4.9 mEq/L;
chloride, 96 mEq/L; bicarbonate, 22 mEq/L; blood urea
nitrogen (BUN), 36 mg/dL; and creatinine, 2.3 mg/dL.
The CPK was 134,470 U/mL; calcium, 6.1 mg/dL; magne-
sium, 3.7 mg/dL; and phosphate, 6.3 mg/mL. The albumin
and total protein had decreased to 2.5 g/dL and 5.0 g/dL,
respectively, and the hemoglobin had decreased to
11.7 g/dL without evidence of bleeding; the level re-
mained stable thereafter. Over the first 24 hours, the
patient had received several liters of fluid and had pro-
duced 2.2 L of urine. Repeat urinalysis was unchanged,
except that the pH had increased to 7.0 and numerous
amorphous casts were present. Indirect immunofluores-
cent staining revealed fragmented and vesicular material
both within casts and free floating that stained for F-actin,
actin depolymerizing factor, and cofilin (Fig. 1).
Over the course of his hospital stay, he remained nono-
liguric. The CPK, AST, and ALT levels steadily declined,
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and the serum creatinine peaked at 6.4 mg/dL on hospital
day 6. He did not undergo renal replacement therapy and
was discharged on day 8 from the hospital with a serum
creatinine of 4.3 mg/dL that was decreasing daily.
DISCUSSION
DR. BRUCE A. MOLITORIS (Director, Nephrology Di-
vision, Professor of Medicine, and Director, Indiana Cen-
ter for Biological Microscopy, Indiana University School
of Medicine, Indianapolis, Indiana, USA): This case rep-
resents a typical presentation of multifactorial acute re-
nal failure (ARF). Prerenal azotemia, cocaine-mediated
vasoconstriction and trauma resulted in acute tubular
necrosis (ATN) secondary to rhabodmyolysis and renal
hypoperfusion. The pathophysiology and clinical aspects
of rhabdomyolysis-induced ATN have recently been re-
viewed [1] and is little changed from the excellent 1996
article by Zager [2]. Therefore, this case will be used as a
model of renal ischemia resulting in cellular actin alter-
ations in epithelial, endothelial, and smooth muscle cells
as a mechanism of cellular injury and death mediating
kidney dysfunction.
The patient was treated aggressively with volume re-
placement and bicarbonate therapy but he remained
nonoliguric for the duration of his hospital stay. Since
the level of serum creatinine increased by greater than
1.5 mg/dL, but the patient did not require renal replace-
ment therapy, I would describe this as moderate ARF.
Although the initial urine analysis was nondiagnostic,
the subsequent presence of hemoglobin, myoglobin, and
muddy brown casts (Fig. 1A) left little doubt as to the
diagnosis and etiology of ATN in this patient. In a pre-
vious case of rhabdomyolysis, secondary to rigorous ex-
ercise, we had the highly unusual advantage of having
obtained an early renal biopsy, taken within 24 hours of
the initiating event, to help delineate the pathophysiology
of clinical ATN. As Figure 2 illustrates, there was severe
proximal tubule injury with loss of apical microvilli, accu-
mulation of proteinaceous material within the lumen, de-
tachment of proximal tubule cells (PTCs), and increased
white blood cells within the peritubular microvascular
space. Unfortunately, the biopsy material was limited to
the cortical region, so the outer medullary area could not
be evaluated.
The pathophysiology of ischemic ARF involves a com-
plex interplay among cell injury, inflammation, and al-
tered renal hemodynamics. While no single overarching
theme can tie the myriad of injurious consequences to-
gether, alterations in the actin cytoskeleton have been
shown to affect multiple cell types and physiologic pro-
cesses within the kidney during and following ischemic
injury. Furthermore, these actin alterations play a well-
documented role in the initiation and extension phases of
ischemic ARF in animal models. Therefore, the purpose
of this Forum is to describe and interrelate the known
abnormalities that occur in epithelial, endothelial, and
smooth muscle cell actin cytoskeletons during ischemia
and reperfusion to what is known about the pathophysi-
ology of ischemic ARF. Finally, exciting actin cytoskeletal
pathways have been documented recently and might pro-
vide yet a further integrative step in the role of actin alter-
ations, cellular injury, and organ dysfunction in ischemic
ARF.
Physiology
The actin cytoskeleton plays an ever increasingly un-
derstood role in mediating interactive processes neces-
sary for cellular and organ structure and function. New
and exciting information regarding the dynamic aspects
of the actin cytoskeleton and its intracellular regulation
is unfolding at a rapid rate. Actin cytoskeletal-surface
membrane interactions mediating such diverse cellular
events as cell polarity, endocytosis, exocytosis, division,
migration, cell-cell and cell-extracellular fluid (ECF) ad-
hesion, signal transduction, and ion channel activation
are part of an ever-growing list of cellular processes de-
pendent upon precise polarization and regulation of actin
assembly and disassembly [3–5]. Ischemia rapidly induces
duration-dependent structural alterations in the cellular
actin cytoskeleton in both in vivo and in vitro studies
[5–9]. Furthermore, recent data now implicate these al-
terations as fundamental to the cellular and organ dys-
function that ensue.
Actin filaments, in concert with actin-binding proteins,
mediate actin-dependent cellular processes. Actin fila-
ments are arranged into “higher order” forms including
a cortical actin network (actin gel), stress fibers (loose
nonparallel bundles), and tight parallel bundles seen in
microvilli [5]. These F-actin structures have different
functions, lengths, and cellular locations. They are influ-
enced differently by cellular regulatory processes, such
as Rho guanosine triphosphatases (GTPases), but their
generation and maintenance comprise a dynamic, energy-
dependent process requiring F-actin assembly and dis-
assembly. Assembly and disassembly of actin filaments
are the central steps in actin-dependent cellular pro-
cesses. The rate of this turnover determines sensitivity
to cellular adenosine triphosphate (ATP) depletion, with
more rapid turnover increasing sensitivity [10]. Actin fil-
aments are polar, with a rapid-growing barbed end and
a slow-growing pointed end [11]. Disassembly occurs
primarily by dissociation at the pointed end, releasing
G-actin bound to adenosine diphosphate (ADP). Once
released, ADP-G-actin undergoes nucleotide exchange
with abundant cytosolic ATP, and the resulting ATP-G-
actin is rapidly bound by thymosin-sequestering proteins
and stored as a high-energy intermediate until needed for
actin polymerization [4, 5, 11].
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Fig. 1. Urinary casts and cellular debris contain actin and actin depolymerizing factor proteins. On day 2 of the hospitalization a fresh urine sample
was processed for urinalysis and the sediment fixed with 4% paraformaldehyde. The sample was stained for F-actin utilizing Texas red phalloidin.
Indirect immnofluorescent staining was used to identify actin depolymerizing factor and also cofilin using specific primary antibodies and fluorescein
isothiocyanate (FITC)-conjugated secondary antibodies for ADF and a CY-5 conjugated secondary antibody for cofilin. Images were obtained using
confocal microscopy with sequential excitation. (A) A phase contrast image of a cellular cast and cellular debris. (B) Texas red phalloidin labeling
indicates the cast has fragments and intact vesicles containing F-actin. (C) Staining for ADF, but selective cofilin staining is not shown separately.
(D) An overlay shows close association of F-actin, ADF, and cofilin. This considerable overlap between F-actin, ADF, and cofilin in casts and debris
is consistent with staining as previously reported in tubular lumens and the urine following ischemic injury in a rat model [20, 36].
In all cells, the assembly and function of actin are
controlled by actin-binding proteins as well as by the
inherent properties of actin [5]. The state of actin as-
sembly depends upon four groups of actin-binding pro-
teins. Sequestering proteins, like thymosins, bind G-actin
and inhibit polymerization by reducing the “effective” or
“free” G-actin concentrations. Other monomer-binding
proteins enhance addition of G-actin at the barbed end
(profilin) or stimulate dissociation at the pointed end
[actin depolymerizing factor (ADF) or cofilin]. Capping
proteins bind to filament ends and stabilize either the
barbed or pointed ends. Severing proteins mediate fil-
ament cleavage, and dynamizer proteins (ADF/cofilin)
function by enhancing filament growth and turnover.
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Fig. 2. Human renal biopsy showing proximal tubule injury. This image
is a representative sample of a kidney biopsy for ARF, kindly provided
by Dr. James Hasbargen, following exercise-induced rhabdomyolysis.
The biopsy, obtained within 24 hours of the event, revealed significant
proximal tubule cell damage with intraluminal accumulation of api-
cal membrane fragments and a detached cell (∗), thinning of proximal
tubular cells to maintain monolayer tubule integrity (arrowhead), and
dividing cells and accumulation of white cells within the microvascu-
lar space in the peritubular area (arrow). The patient required renal
replacement therapy but did regain complete renal function.
Fig. 4. Microvascular permeability defect following ischemic injury. A 3000 D rhodamine-labeled dextran and a 500,000 D fluorescein isothiocyanate
(FITC)-labeled dextran were injected via the tail vein into a rat following 24 hours of reperfusion after 45 minutes of ischemia and were viewed
using intravital two-photon microscopy [63, 81]. Images obtained from the same field. (A) The extent of microvascular extravasation of the high-
molecular-weight dextran. (B) The extent of microvascular extravasation of the low-molecular-weight dextran. (C) A color overlay of (A and B),
with the low-molecular-weight dextran in red and the high-molecular-weight dextran in green. The large arrow in (C) indicates an area of diminished
microvascular flow and extravasation of both dextrans. The arrowhead shows only the small red dextran moving into the interstitial space.
Fig. 3. Urinary cast formation following clamp ischemia in a rat model.
Intravital two-photon microscopy of a rat cortex following 45 minutes
of renal ischemia and intravenous infusion of a 3000 molcular weight
Texas red dextran and a 500,000 molcular weight fluorescein isothio-
cyanate (FITC) dextran. The tubule lumen appears red as the small red
dextran is freely filtered across the glomerulus. The intraluminal vesic-
ular blebs appear as dark spheres as they do not contain the dextran
material. The large green dextran outlines the peritubular microvas-
culature and dark figures within this microvasculature represent cells
moving through it. A cast (arrow) is shown in a distal tubule when
distal tubule cells can be identified by lack of cellular endocytosis of
red dextran [81]. Shown on the right is a proximal tubule with endo-
cytic uptake of the red dextran (arrowhead). For a movie showing the
dynamic process, go to http://www.blackwellpublishing.com/products/
journals/suppmat/ki66/ki66-2 818/ki66-2.mov.
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Nucleation proteins mediate and enhance actin filament
formation. The coordinated interactions of actin-binding
proteins result in the continual dynamic remodeling of
the cytoskeleton and allow for rapid responses to external
stimuli and internal signaling cascades [3, 4, 11].
Pathology
Severe reductions in renal blood flow produce char-
acteristic, rapidly occurring, and duration-dependent ef-
fects on the actin cytoskeleton of numerous renal cell
types. Although best described for epithelial cells, docu-
mentation of effects on endothelial and smooth muscle
cells now suggests that these alterations are independent
of the cell type [6–9, 12, 13]. Even very short ischemic in-
sults provoke cellular changes in surface membrane po-
larity and junctional complexes mediated by the actin
cytoskeleton. The apical microvillar region of PTCs is
particularly sensitive to ischemic insults, and rapid and
severe but repairable damage occurs [13]. Within 5 min-
utes of ischemia, the microvillar F-actin core and its over-
lying plasma membrane show signs of degeneration [13,
14]. The plasma membrane no longer maintains its finger-
like microvillar structure, but becomes more amorphous,
while the internal F-actin core begins to deteriorate. With
longer ischemic insults, the plasma membrane and mi-
crovillar F-actin cores degenerate further. This is easily
seen in Figure 2, which indicates that similar events oc-
cur as early events in clinical ischemic ATN. The reason
for this extreme sensitivity, compared to other tubular ep-
ithelial cells, might relate to the recently documented role
of actin in endocytosis [15, 16]. Since PTC apical mem-
branes carry out extensive endocytic events [17], the rate
of actin polymerization must be very rapid, rendering it
highly susceptibile to ischemic injury as ATP depletion
occurs. Proximal tubule cell substrate requirements and
energy utilization also render it particularly susceptible
[18].
The actin-binding protein family of ADF and cofilin
proteins plays a critical role in the apical microvilli break-
down in response to ischemia [19–21]. ADF, an impor-
tant regulator of F-actin dynamics, binds F-actin in a
pH-dependent manner and mediates F-actin severing
and pointed-end depolymerization [22, 23]. The phos-
phorylated form of ADF is inactive and cannot bind
actin [24–26]. LIM kinases, activated by Rho GTPases
and testicular protein kinases, phosphorylate ADF/cofilin
specifically at Ser-3 and thereby inhibit its function [22].
“Slingshot” is a recently described family of phosphates
that dephosphorylate ADF/cofilin and thereby activate
it [27]. Renal ischemia induces rapid dephosphoryla-
tion/activation and relocalization of ADF in PTCs [20, 21]
from a diffuse cytoplasmic pattern to the surface mem-
brane and to plasma-membrane-bound vesicles that have
been shed into the PTC lumen [20, 21]. The mechanism
of ADF penetration into the apical microvillar region
involves ischemia-induced dissociation of tropomyosins
from the terminal web [28]. Tropomyosins, a family of
F-actin binding and stabilizing proteins, are localized to
the terminal web, a region where the ADP-actin-rich mi-
crovilli microfilament pointed ends are located [29, 30].
Several in vitro biochemical and structural studies have
demonstrated that ADF competes with tropomyosin for
F-actin binding [31, 32]. In vitro studies also suggest
that localization of tropomyosin at the terminal web
not only stabilizes microfilaments but protects the fila-
ments from binding by active ADF/cofilin proteins, thus
preventing filament severing and depolymerization. In
addition, ezrin, a phosphorylated protein that mediates
microvillar F-actin to surface membrane binding, dis-
sociates during ischemia and frees the surface mi-
crovillar membrane from its cytoskeletal attachments
[33]. Therefore, ischemia-induced tropomyosin and ezrin
dissociation from the terminal web and microvillar mi-
crofilaments allows for the rapid binding and destabi-
lization of the apical membrane domain by ADF/cofilin
proteins through disruption of microvilli microfilament
cores [28, 33]. Finally, pharmacologic disruption of PTC
F-actin induces apoptosis [34], and cofilin activation and
mitochondrial translocation are necessary for apoptosis
[35]. Therefore, cofilin and ADF activation play multiple
roles in cell injury and cell death.
In PTCs, these apical microvillar alterations form
membrane-bound, free-floating extracellular vesicles
termed “blebs” that either undergo internalization or are
released into the tubular lumen [20, 21, 36–39]. These
transformations substantially reduce apical membrane
surface area, thus decreasing the effective reabsorption
area (Fig. 2). In addition, the membrane blebs and cyto-
plasmic contents shed into the tubule lumen often aggre-
gate and cause tubular obstruction. That similar processes
hold for human ischemic ATN is suggested by the staining
pattern of the cast shown in Figure 1. F-actin, ADF, and
cofilin were identified within the cast and as free-floating
vesicular components within the urine, as was seen fol-
lowing ischemic injury in rats [20, 21, 36]. Both loss of
surface membrane and tubular obstruction decrease the
glomerular filtration rate (GFR), a hallmark of ischemic
ARF [39]. Obstruction of the tubular lumen eliminates
glomerular filtration within that nephron by increasing in-
tratubular pressures to levels inconsistent with filtration.
The formation of such a cast was recently documented in
a rat following renal artery clamp ischemia, using intrav-
ital multiphoton microscopy (Fig. 3) (Quick Time movie
is at the URL www.nephology.iupui.edu/kiforum3). Nu-
merous surface membrane vesicles/blebs and other in-
tralumenal material aggregate within the distal tubular
lumen and then move as a unit. Casts can be passed
into the urine or remain within the tubule and cause
obstruction.
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Two additional PTC-related events decrease GFR fol-
lowing ischemic injury. Reductions in proximal tubule ion
and water reabsorption result in high distal delivery of
Na+, K+, Cl− and high distal flow rates. This, in turn,
via tubular glomerular feedback (TGF), produces affer-
ent arteriole constriction and its attendant reduction in
GFR. Finally, opening of tight and occluded junctions re-
sults in the unregulated paracellular movement of ions
and water, thereby causing increased backleak, the third
mechanism of reduced GFR following ischemic injury
[39]. In an eloquent series of experiments in transplant
ATN, the laboratory of Brian Myers showed that afferent
vasoconstriction secondary to activation of TGF, tubu-
lar obstruction, and backleak across open tight junctions
are responsible for the decrease in GFR [40–42]. There-
fore, ischemia-induced alterations in PTCs in large part
account for the reduction in GFR occurring following is-
chemic injury.
In addition to the apical membrane changes, cellular
junctional complex dissociation allows membrane lipids
and integral and peripheral membrane proteins to dif-
fuse laterally into the alternate surface membrane do-
main [12, 43, 44]. This loss of membrane polarity creates
a more homogenous surface membrane without unique
apical or basolateral membrane regions. Dissociation of
cellular junctions also reduces cell-to-cell contacts and
causes unregulated paracellular diffusion of water, ions,
and macromolecules [12, 44, 45]. The now nonpolarized
renal epithelial cells can no longer reabsorb and transport
appropriately.
Both microvillar breakdown and loss of cellular po-
larity during ischemia are preceded by structural alter-
ations in the actin microfilament network [13, 14, 43, 46].
These cytoskeletal changes reflect the severity and dura-
tion of the ischemic injury. The microvillar actin cores,
the cytoskeletal meshwork of the terminal web, and the
cortical actin of the epithelial cell are disrupted. The
concentration of F-actin in the cell increases with the
formation of F-actin aggregates in the cytoplasm [13].
We recently elucidated the mechanism responsible for
unregulated actin polymerization and aggregation dur-
ing ischemia [47]. With cellular ATP depletion, genera-
tion of ATP-G-actin from ADP-G-actin is not possible.
Since thymosins, far and away the most quantitatively im-
portant actin-sequestering proteins in mammalian cells,
cannot bind ADP-G-actin, it accumulates and, after
exceeding its critical concentration, polymerizes. How-
ever, instead of polymerizing in a regulated fashion,
large cytosolic aggregates accumulate, especially in the
perinuclear region [6, 43, 48] and also near the junctional
complexes and basolateral membrane [49]. The lack of
active Rho A GTPase might be in part responsible for
this abnormal F-actin distribution [50]. The well-known
activation of ADF/cofilin proteins during ATP depletion
accentuates this process by increasing F-actin depolymer-
ization and thereby providing a source of more ADP-G-
actin that cannot be sequestered and neutralized. Finally,
the rapid depletion of cellular ATP-G-actin during cellu-
lar ATP depletion implies its rapid utilization [47].
Microvascular dysfunction
Recent studies indicate a central role for microvascu-
lar injury with attendant disruption of the endothelial
cell actin cytoskeleton in the pathophysiology of ischemic
ARF [51–53]. In particular, endothelial cell injury, in-
cluding cell swelling, altered cell-cell attachment, and re-
duced endothelial cell-basement membrane attachment
are some of the alterations that have been observed fol-
lowing ischemic injury [52, 54]. Functional consequences
of these morphologic alterations include reduced blood
flow to affected microvascular beds secondary to altered
vascular reactivity, increased leukocyte adherence and
extravasation, altered coagulation due to endothelial dys-
function, and increased interstitial edema secondary to
increased endothelial permeability [55].
Specialized cellular junctions maintain endothelial
cell-cell contacts. Tight junctions are more prominent
in “tight” vascular beds such as between the endothe-
lial cells of the cerebral vasculature forming the blood-
brain barrier, whereas they are sparse and simplified
in “leaky” vascular beds such as post-capillary venules
[56]. Cadherin-containing adherens junctions are ubiqui-
tous between endothelial cells throughout the vascula-
ture [56]. Recent studies highlighting differences in the
molecular composition of junctional complexes within
the kidney provide insight into the potential functional
differences of the cellular junctions in these vascular
beds [57–59]. Disruption of endothelial adherens junc-
tions in vivo, by the use of an inhibitory antibody to
VE-cadherin, induces gaps between endothelial cells,
increases endothelial permeability, and promotes the
accumulation of inflammatory cells in coronary and pul-
monary vascular beds [60]. Furthermore, in vitro studies
suggest that the interaction of endothelial cell-cell junc-
tions with the actin cytoskeleton plays an important role
in regulating endothelial paracellular transport [61]. Data
also indicate that microvascular congestion and localized
interstitial edema follow renal ischemia [55, 62, 63]. How-
ever, a direct role for altered junctional function in in-
creased permeability following ischemic injury is lacking.
The finding that circulating von Willebrand factor
(vWF) increased following renal ischemic injury further
suggests that the renal vascular endothelium is injured
[63]. In other organ systems, release of vWF from the
endothelium occurs in a biphasic fashion in response to
ischemia and reperfusion [64, 65]. These studies suggest
that hypoxia, as well as reperfusion, mediate endothe-
lial release of vWF via potentially different mechanisms.
Furthermore, inflammatory processes can contribute to
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endothelial vWF release [66]. The peak elevation of circu-
lating vWF following renal clamp ischemia was monopha-
sic and occurred 24 hours after the ischemic insult.
Therefore, continued hypoxia, reperfusion injury, and/or
inflammatory processes all could be playing a role in vWF
release [63]. The utility of such a finding might lie in the
ability to characterize the extent of the underlying injury
by circulating markers of endothelial injury and thus pro-
vide a useful clinical correlate for disease severity, prog-
nosis, and therapeutic intervention.
Examination of the morphologic alterations in renal
microvascular endothelial cells revealed that the normal
structure of the actin cytoskeleton is disrupted during
ischemia [63]. Alterations of the normal actin cytoskele-
ton of endothelial cells in cell culture have been demon-
strated with ATP depletion and with H2O2 as a model
of oxidant-mediated reperfusion injury. ATP depletion
rapidly and reversibly disrupts the normal cortical and
basal F-actin structures in endothelial cells and results
in F-actin aggregation and polymerization [8, 67, 68].
Oxidant-mediated endothelial cell injury also disrupts
the cortical actin band in cultured endothelial cells [69–
71]. The actin cytoskeleton in endothelial cells of the re-
nal microvasculature subjected to ischemic injury in vivo
was most prominent immediately following the ischemic
insult [63]. There was an increase in F-actin polymer-
ization and aggregation at the basal and basolateral as-
pects of endothelial cells following ischemia. This F-actin
polymerization and aggregation were reminiscent of the
alterations observed following ischemia in proximal tubu-
lar epithelial cells [6, 43, 48] and renal vascular smooth
muscle cells [6].
Alterations in the actin cytoskeleton of renal mi-
crovascular endothelial cells preceded alterations in VE-
cadherin staining at endothelial cell-cell junctions and
increases in endothelial permeability [63]. These find-
ings are consistent with a mechanism by which loss of
integrity of the actin cytoskeleton contributes to break-
down of the actin-associated adherens junctions and con-
tributes to the concomitant permeability defect. Much of
the current knowledge regarding the mechanisms reg-
ulating endothelial cell-cell interactions during ischemic
and oxidant injury has come from in vitro models utilizing
cultured endothelial cells. ATP depletion of endothelial
cell monolayers and exposure of endothelial monolayers
to oxidants such as H2O2 have both been demonstrated
to increase endothelial permeability and intercellular gap
formation [72, 73]. Increased endothelial permeability in
these models also has been associated with internaliza-
tion of VE-cadherin from endothelial adherens junctions
[74].
Vascular reactivity following ischemic injury might also
in part be due to actin cytoskeletal alterations. Studies
evaluating the effect of ischemia on vascular smooth mus-
cle cells revealed disruption and aggregation of F-actin
in all renal vessels studied [6]. Furthermore, the effects
worsened with reflow in the corticomedullary vasa recta
area. The authors [6] postulated that the lack of orga-
nized F-actin and increased F-actin polymerization could
in part be responsible for the known loss of autoregula-
tion of renal blood flow following ischemic injury [75].
Additional data implicate actin in the regulation of vas-
cular tone with a potential causative role in reduced re-
nal blood flow after ischemic injury. Endothelial nitric
oxide synthase (eNOS) is directly regulated by the actin
cytoskeleton with increases in F-actin associated with re-
duced eNOS activity [76]. This, taken in conjunction with
data indicating that eNOS activity was necessary for min-
imizing ischemic ARF with endothelial cell infusion [52],
suggests that endothelial NO generation might be re-
duced because of endothelial cell actin polymerization
during ischemia. This could be particularly true in the
cortical medullary region, where continued hypoxia ex-
ists for prolonged periods secondary to poor reperfusion
[77].
These problems are compounded by the more rapid
and complete reperfusion of the renal cortical area as
compared to limited reflow of the cortical medullary area
[55]. This rapid reperfusion of the cortex leads to rapid
PTC repair, unlike the continued hypoxia in the cortical
medullary area that results in progressive cellular injury
of endothelial, smooth muscle, and epithelial cells. Since
most pathology specimens of human ATN come from ei-
ther autopsy specimens or a renal biopsy taken from non-
recovering ATN, it is quite possible that the early phase
of injury to cortical PTC is not apparent. Therefore, the
lack of renal biopsies within the first 24 hours following
the initiation of ARF has limited our ability to judge the
utility of animal models [78, 79].
The development of Tie2 mice [80] and the utilization
of two-photon intravital microscopy [81] for visualizing
the permeability defect in the renal microvasculature fol-
lowing ischemia gave us the ability to study renal mi-
crovascular endothelial injury (Fig. 4). The power of this
imaging technique was demonstrated by the ability to
simultaneously evaluate the disparity in the permeabil-
ity defect of two different-sized fluorescent probes, and
observe a correlation, in a timed image series, between
alterations in blood flow and severity of the perme-
ability defect [63]. These data imply a direct relation-
ship between the extent and duration of continued
reduced blood flow and the increased permeability de-
fects between endothelial cells. While these observa-
tions were limited to the cortical area of rats because of
technical considerations, the permeability defect in the
corticomedullary area presumably could be even more
pronounced than that observed in the cortical microvas-
culature [55, 77]. Implications for leakage of plasma from
the vascular space and increased interstitial edema, es-
pecially in the corticomedullary area, include further
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diminishment of the compromised medullary blood flow
by extrinsic compression of peritubular capillaries [82]
and by hemoconcentration, as observed in other organs
[83].
QUESTIONS AND ANSWERS
DR. JOHN T. HARRINGTON (Division of Nephrol-
ogy, Tufts-New England Medical Center, Boston, Mas-
sachusetts): Could you tell us a bit more about the normal
structure and function of actin depolymerizing factor and
what regulates it?
DR. MOLITORIS: ADF/cofilin is a noncapping, calcium-
independent, F-actin binding/severing protein that also
sequesters G-actin and is regulated by pHi and phos-
phorylation [22]. It contains a nuclear localization se-
quence [84] and binds to PI and polyphosphoinositides
[85]. At a low pHi (<7.1), it binds to F-actin and forms
1:1 complexes with individual subunits [86]. As pHi
increases, it becomes destructive, severing F-actin and
leaving uncapped barbed ends. Phosphorylated (serine-
3) ADF accounts for 15% to 60% of total ADF [25]
and is an active severing protein only in the dephos-
phorylated form. Two protein kinase families, LIMK1/2
and TESK1/2, are tissue-specific kinases that specifi-
cally phosphorylate and inactivate ADF/cofilin at the
N-terminal serine residue [87, 88]. The LIM kinase fam-
ilies are activated through phosphorylation mediated by
p21-activated kinase-1 (PAK1), p21-activated kinase-4
(PAK4), or Rho-associated kinase (ROCK) [89]. In turn
PAK1 and PAK4 are activated through interactions with
Rac/Cdc42, and ROCK is activated through Rho. TESK
protein kinases are stimulated by an integrin-mediated
signaling mechanism. The phosphatase protein family,
slingshot, dephosphorylates ADF/cofilin and activates
ADF/cofilin activity [90]. Very recent information in-
dicates that the ADF/cofilin family also is involved in
mediating receptor-mediated endocytosis and apoptosis.
During ischemia, rapid dephosphorylation of ADF
increases its activity and directly leads to F-actin de-
struction. Being able to prevent this activation would
minimize morphologic changes in epithelial, endothelial,
and smooth muscle cells. However, at present there is
no known inhibitor of slingshot, and the kinases appar-
ently have minimal function under conditions of ATP
depletion.
DR. HARRINGTON: In the early 1970s, Leaf and col-
leagues at the Massachusetts General Hospital described
microvascular injury with endothelial cell swelling as a
critical finding in ischemic renal injury [54]. Do your ob-
servations fit with those earlier observations?
DR. MOLITORIS: It is unfortunate that the early ob-
servations by Leaf and colleagues were not extended.
Recent information from several laboratories indicate
that, indeed, endothelial cell injury and involvement
in ischemic ARF are of critical importance. Using the
Tie2 mouse model, Sutton et al showed early duration-
dependent alterations in endothelial cell actin cytoskele-
ton that lead to permeability changes [63]. Goligorsky’s
laboratory showed the importance of eNOS in the pro-
tection provided by infused endothelial cells [52]. Still
unstudied are the microvascular alterations of the corti-
cal medullary region, a region of minimal reflow where
continued epithelial cell injury occurs during the reper-
fusion period.
DR. RONALD PERRONE (Division of Nephrology,
Tufts-New England Medical Center): You beautifully de-
scribed how renal ischemia affects multiple subcellular
pathways. I would like to know your thoughts regard-
ing potential therapeutic interventions including inter-
ventions targeting more than one pathophysiologic event.
DR. MOLITORIS: The pathophysiology of ischemic
and septic ARF is multifactorial in nature. Vasocon-
striction, inflammation, coagulation, apoptosis, and cy-
toskeletal alterations are several of the broad categories
involved. Within each category several areas also must be
considered. For example, vasoconstriction occurs at the
macrovascular level and is mediated by many factors such
as endothelin. At the microvascular level, it is mediated
by many factors including the lack of NO. Therapeutic
interventions must take into account all these factors, so
I do not believe a “silver bullet” exists. Several years ago
we and other investigators suggested considering a mul-
tifaceted approach, such as the present-day approach to
cancer therapy [91].
DR. PERRONE: In your opinion, what is the potential
time course for intervention?
DR. MOLITORIS: The earlier the better, beginning with
preventive measures in high-risk patients and extending
through rapid treatment of newly diagnosed ARF. We
recently reviewed the rationale behind early diagnosis
and therapy [77]. We have postulated that an “extension
phase” exists in ischemic ARF that is mediated by on-
going endothelial injury and lack of reperfusion, espe-
cially to the cortical medullary region. The existence of
this phase would make early treatment of paramount im-
portance. However, before we can make progress in this
area, we must deal with several obstacles that currently
limit our overall approach to the patient with ARF. First,
we must realize that ARF is an independent risk factor
for mortality, as has now been documented in several
clinical studies, and convince our clinical colleagues that
our early involvement in patient care is beneficial. Then
we must develop criteria that will allow us to identify
high-risk patients so that adequate preventive measures
can be employed [92]. Finally, we must develop surveil-
lance methods that allow for early diagnosis and ways to
quantify the extent of initial injury. Fortunately several
groups of investigators are working diligently in these last
two areas to provide the information necessary. Also, the
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American Society of Nephrology (ASN) has established
a task force in ARF that is discussing many of these issues
and is very interested in establishing an ARF clinical tri-
als network to hasten progress in the treatment of ARF.
Specifically, the identification of biomarkers of ARF is an
urgent issue for this group. Qualitative and later quanti-
tative markers will allow for rapid progress. At present,
I am a believer in measuring serum creatinine more fre-
quently (until a better marker is available) to help with
the early diagnosis. Measuring the serum creatinine level
only once every 24 hours in a high-risk patient, such as
a postoperative surgical patient with preexisting chronic
renal disease, is just not frequent enough. Perhaps other
markers, such as cystatin C, will provide earlier detection
in our patients [93].
DR. PERRONE: The role of the primary epithelial cell
cilium has been extensively evaluated in polycystic kidney
disease. Have you evaluated the role of cilia in ATN?
DR. MOLITORIS: To my knowledge, there have been
no reports evaluating a role for the cilia in ATN.
DR. BERTRAND JABER (Division of Nephrology, Tufts-
New England Medical Center): Circulating endothelial
cells have been detected in patients with chronic kidney
disease [94]. Are circulating endothelial cells detectable
in sepsis and ARF? They could be surrogate markers for
acute endothelial injury.
DR. MOLITORIS: Yes, circulating endothelial cells have
been isolated from patients with sepsis [66, 95]. They have
not been isolated from patients with ATN alone, but I am
not sure anyone has tried to do this. I am hopeful that in-
vestigations are under way that will identify unique serum
markers of ATN, and endothelial cell proteins might be
a logical target.
DR. JABER: In experimental ARF, the administra-
tion of high-dose recombinant human erythropoietin
(rHuEpo) accelerates recovery of renal function [96].
Can you speculate on the role of rHuEpo as a potential
growth factor for tubular cell regeneration?
DR. MOLITORIS: As you know, many growth factors
have a positive effect on GFR in ischemic models of ARF.
Part of this effect is mediated by hemodynamic forces
that favor increased filtration regardless of the baseline
GFR. However, other effects, such as minimizing apop-
tosis, might be playing an important role. It has always
been hard for me to conceive of how a growth factor can
influence the GFR within the first 24 hours primarily by
increasing tubular cell regeneration.
DR. HARRINGTON: We know that Epo receptors exist
in all renal tubular cells and that Epo expression is abol-
ished within a few hours of inducing ischemic ARF in
rats. At the 2003 meeting of the ASN, abstracts showed
that Epo protects the kidney via nuclear factor-jB (NF-
jB [abstract; Westenfelder C, et al, J Am Soc Nephrol
14:272A, 2003] and by inhibiting the caspase cascade [ab-
stract; Sharples EJ, et al, J Am Soc Nephrol 14:273A,
2003]. Could you comment on those papers or simply tell
us about Epo’s protective effects?
DR. MOLITORIS: Dr. Christof Westenfelder has estab-
lished a link among erythropoietin, inflammation, and
apoptosis [97]. His data indicate that cytokine-mediated
activation of NFkB decreases erythropoietin transcrip-
tion. This decrease in turn results in loss of Epo’s permis-
sive and active effects on inhibiting apoptosis. These data,
along with the recent work from Kelly’s and Dagher’s lab-
oratories [98], suggest an important role for apoptosis in
the pathophysiology of ATN. The renal community has
experience with erythropoietin administration in numer-
ous types of patients, so Epo will be a likely candidate for
the “growth factor” aspect of combination therapy in the
treatment or prevention of ARF.
DR. JABER: The use of high-dose rHuEpo in ARF has
to be carefully analyzed because this drug can increase
endothelin production, and this increase can lead to re-
sistance to the vasodilating action of NO [99]. Would you
agree that these biologic effects can be deleterious in crit-
ically ill patients with sepsis, patients who have an already
compromised microvasculature?
DR. MOLITORIS: Most therapies come with trade-offs
and potential side effects. Erythropoietin increases en-
dothelin production and can potentially increase vaso-
constriction within the kidney. However, we do know that
Epo receptors within the kidney are rapidly up-regulated
in ATN. Therefore we should be thinking about more
physiologic doses, and not the “industrial” amounts we
use to enhance red blood cell production. Furthermore,
preconditioning with Epo protects against subsequent is-
chemic injury in the kidney [100].
DR. IRA M. HERMAN (Professor, Department of Phys-
iology, Tufts University School of Medicine): Have you
thought about why the renal epithelial cells’ apical actin
cytoskeleton, associated with brush border, is so particu-
larly sensitive to disassembly? Wouldn’t you also expect
that the actin network associated with the adherens junc-
tions, that is, the belt of actin associated with the terminal
web, would also be similarly affected?
DR. MOLITORIS: The sensitivity of the actin cytoskele-
ton to ATP depletion is related to the rate of actin
turnover. Apical membrane microfilaments have a very
rapid turnover secondary to the rapid rate of endocytosis
[15, 16]. We have shown that the junctional complex also
undergoes rapid alterations with ischemic injury [12, 44],
but for this Forum I have concentrated on the microvilli
because of their role in loss of apical membrane surface
area and tubule obstruction.
DR. HERMAN: The apical actin reorganization ob-
served in the renal epithelial cell during acute renal fail-
ure is reminiscent of the apical cytoskeletal response
that occurs in the gastrointestinal system following en-
teropathogenic Escherichia coli challenge. That is, one
observes an effacing lesion, and the actin filaments in the
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microvilli are disassembled and then re-assembled as a
pedestal downstream of the bacterial type III secretion
system. In this case, as might be the case in the renal
epithelium, the disassembly is mediated by a calcium-
dependent protease and ezrin-mediated reorganization
[101].
DR. MOLITORIS: Ezrin has clearly been shown to un-
dergo dephosphorylation during ischemia and dissociate
from the surface membrane; this alteration destabilizes
the microvillar membrane [33]. However, there is no ev-
idence for calpain-mediated actin alterations within this
domain.
DR. HERMAN: Bruce, have you considered whether the
anomalies in flow are related to the mural cells associating
with the peritubular capillaries? It has been well studied
from the time of our first characterization [102] that per-
icytes are smooth-muscle-like contractile cells capable of
regulating microvascular flow. Local constriction of peri-
cytes could control capillary blood flow, and the pericyte
response to endothelin-1 could be causally linked to the
observable anomalies.
DR. MOLITORIS: Pericytes have not been studied in is-
chemia within the kidney. They are known to be located
around the renal microvasculature in a sparse fashion.
Dr. Connie Temm is currently looking at the intercon-
version/activation of renal pericytes into smooth muscle
cells following ischemia. She uses the expression of alpha
actin as the distinguishing feature of smooth muscle cells
(personal communication).
DR. HERMAN: There are numerous examples that per-
icyte foot processes cover many, many endothelial cells,
and there are as many examples revealing the circumfer-
ential disposition of these cells, which share the basement
membrane with the capillary endothelium. The beautiful
images that you showed (Fig. 4) are possibly graphic rep-
resentations of the focally constricted nature of the capil-
lary wall, which might be related to endothelin-mediated
pericyte contraction and capillary constriction.
DR. HARRINGTON: Could you comment on the new so-
called “micro-MRI” methods that estimate tubular func-
tion and interstitial inflammation in experimental animals
[103]?
DR. MOLITORIS: I would refer you to the excellent re-
view in which Dr. Robert Star discusses the use of MRI
methods to advance the understanding of ischemic ATN
[104]. He has used these techniques to study PTC function
and inflammation in rats and mice. There is the possibil-
ity that these techniques will soon be available for clinical
studies.
DR. V. S. BALAKRISHNAN (Division of Nephrology,
Tufts-New England Medical Center): Is there much in-
formation on the transcriptional regulation of ADF? If
so, could this be a potential target?
DR. MOLITORIS: Actin depolymerizing factor tran-
scription is under the control of cytosolic G-actin lev-
els [22]. I think the target in minimizing ADF activation
during ischemia will be transient inhibition of the SSH
(slingshot) phosphatase responsible for its activation.
DR. DILIP K. PAHARI (Fellow, Division of Nephrology,
Tufts-New England Medical Center): Heat-shock proteins
(HSP) hasten recovery of acute renal failure. Has anyone
studied the effect of HSP on depolymerization of actin
filaments?
DR. MOLITORIS: Dr. N. Siegel’s laboratory has shown
an association between HSPs and F-actin during the
reperfusion phase in renal ischemia [105]. Eric Shelden
has shown that HSP-27 associates with the basolateral
boundaries of ATP-depleted cells [9]. However, there is
no apparent direct association between HSPs and the reg-
ulation of actin polymerization.
DR. HARRINGTON: It appears that a great deal of the
damage from renal ischemia occurs during the reper-
fusion phase, just as in other organs. What specifically
causes the microvascular problems during reperfusion?
DR. MOLITORIS: The defect in microvascular flow
following ischemic/septic injury is multifactorial. En-
dothelial cell swelling, increased permeability, thrombin
activation/generation leading to coagulation, and the in-
flammatory cascade including white blood cell activation
and cytokine generation, endothelin-mediated vasocon-
striction, and reactive oxygen species mediated several
effects, including decreases in NO-mediated vasculature
vasodilatation. This is why I believe we must consider a
multifaceted approach to therapy if we are going to be
successful. However, some potential therapeutic agents
have multiple effects. For instance activated protein C is
known to be anti-apoptotic and anti-inflammatory, and
it prevents thrombotic events as it inactivates thrombin.
Finally, delivery of any agent to the involved area de-
pends on microvascular flow. Therefore, maintaining or
re-establishing this flow is of paramount importance. This
is why preventive or early therapy is essential.
DR. JABER: How far are we from a new blood or urinary
marker of renal injury that would be more sensitive than
the serum creatinine, which rises later in the process?
DR. MOLITORIS: We are entering a new phase of explo-
ration for the “troponin” equivalent for ischemic/septic
ATN. Several investigators are now using proteomic ap-
proaches on both blood and urine. Cystatin C is one
available serum marker recently shown to be superior
to creatinine in diagnosing early ARF [93]. Other mark-
ers remain investigational like the proteins recently de-
scribed from the laboratories of Star and Bonventre [106,
107].
DR. ANDREW S. LEVEY (Division of Nephrology,
Tufts-New England Medical Center): Do we know any-
thing about the actin cytoskeleton in chronic kidney
disease?
DR. MOLITORIS: To date I know of no actin cytoskeletal
abnormalities directly related to the pathophysiology of
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chronic kidney disease. This will be an interesting area of
research, especially at the golmerular cell level.
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